利培酮治疗复发精神分裂症1633例临床观察

目的：了解利培酮治疗复发精神分裂症患者的疗效与安全性。方法；在全国各大区近40家医疗机构收集复发精神分裂症病人1633例，以可变剂量利培酮治疗，以简明精神病评定量表（BPRS）、临床疗效评定、看护者疗效评定等评定疗效，以不良反应症状量表、合并用药情况，实验室监测评价安全性。结果：根据BPRS总分减分率评定疗效达显著好转或基本痊愈者为87．1％；临床评定疗效达痊愈或显好者为78．1％，看护者评定为很有效者为53．0％。结论：对于不同年龄的复发精神分裂症病人，利培酮是一个安全、有效的新型抗精神病药，一般剂量≤4mg/d即有明显疗效，主要不良反应为锥体外系症状，病人的服药依从性良好。

A clinical trial of risperidone in the treatment of 1633 recurrent schizophrenic patients

Objective:To investigate the efficacy and safety of risperidone in the treatment of recurrent schizophrenia. Method:1 633 patients were recruited from 40 medical institutions in China and treated with risperidone of flexible dosage.The efficacy was evaluated with the brief psychiatric rating scale (BPRS),the clinical global impression scale (CGI),the clinician's rating and care giver's rating.The safety was evaluated with the treatment emergent symptom scale (TESS) and the laboratory testing. Results:According to the reduction rate of BPRS,87 1% patients improved significantly or recovered. Conclusion:It is suggested that risperidone is effective and safe at the dose of 4mg/d or less in the treatment of recurrent schizophrenia,and the patients have good compliance.The common side effect is mild EPS.